Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

NEXT STORY
ADMA Biologics Announces Data Presented at IDWeek 2019
PREV STORY
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kura Oncology Added to Nasdaq Biotechnology Index

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments

BEVERLY, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

Medical Devices Outsourcing Market to Expand at 11.6% CAGR till 2018 owing to Increasing Demand for Quality Healthcare Services: Transparency Market Research

Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- A new report has been ...

author_avatar
NASDAQ Market News